Frédérique O. P.
- Country
- France
- Department
- Hematology
Research Overview
- Efficacy and Safety of Etentamig and Daratumumab Versus Daratumumab and Combination Therapy in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma
- Phase 2 Study of Belantamab Mafodotin and Mezigdomide in Patients with Relapsed/Refractory Multiple Myeloma Following BCMA-Targeting CAR-T or Bispecific Antibody Therapy
- Phase 3 Study of Isatuximab, Lenalidomide, and Dexamethasone ± Bortezomib in Non-Frail, Transplant-Ineligible Elderly Patients with Newly Diagnosed Multiple Myeloma
Data & Insights
Has run more than one trial at 98 of 177 partner sites.
Specializations
Multiple Myeloma Treatment Innovation
This investigator specializes in pioneering research for multiple myeloma treatment, with particular emphasis on novel therapeutic combinations and treatment strategies.
- Newly diagnosed multiple myeloma therapies
- Transplant-ineligible patient treatments
- Innovative drug combinations
Key focus includes developing treatment protocols for both newly diagnosed and relapsed cases.
Advanced Therapeutic Approaches
Expertise in evaluating targeted therapies and investigating the efficacy of various treatment durations and combinations.
- Continuous vs fixed duration treatments
- Minimal residual disease assessment
- Novel agent combinations
Specializes in optimizing treatment strategies for different patient populations.
Elderly Patient Care
Dedicated research focus on geriatric oncology with specialized treatment approaches for elderly multiple myeloma patients.
- Age-adapted therapy protocols
- Non-frail elderly patient treatments
- Maintenance therapy strategies
Emphasis on developing effective and tolerable treatment regimens for older patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.